Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2 ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России, 355017, Россия, Ставрополь, ул. Мира, д. 310
Список исп. литературыСкрыть список 1. Беккер РА, Быков ЮВ, Быкова АЮ. Патофизиологические механизмы двусторонней связи аффективных и тревожных нарушений с патологией печени и желчевыводящих путей. Психиатрия и психофармакотерапия. 2021; 5: 31–40. 2. Alekseeva AS, Beloborodova E, Rachkovskiy M, Naumova EL, Lambrov EG, Philippova LP. Serotonin metabolism parameters in patients with chronic hepatitis and livercirrhosis. Bull Exp Biol Med. 2008;146(5):577-9. DOI: 10.1007/s10517-009-0353-1 3. Al-Harthy N, Kumagi T, Coltescu C, Hirschfield GM. The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology. 2010;52(2):562-70. DOI:10.1002/hep.23683 4. Anderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep. 2003;52(9):1-85. 5. Baraldi S, Hepgul N, Mondelli V, Pariante CM. Symptomatic Treatment of Interferon Alpha Induced Depression in Hepatitis C: a Systematic Review. J Clin Psychopharmacol. 2012;32:531-43. DOI: 10.1097/JCP.0b013e31825d9982 6. Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP. Systematic review of genuine versus spurious side‐effects of beta‐blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol. 2013;168:3572-9. DOI: 10.1016/j.ijcard.2013.05.068 7. Biagini MR, Tozzi A, Milani S, Grippo A, Amantini A, Capanni M, Galli A, Surrenti C. Fatigue in primary biliary cirrhosis: a possible role of comorbidities. Eur J Gastroenterol Hepatol. 2008;20(2):122-6. DOI: 10.1097/MEG.0b013e3282f1cbda 8. Bianchi G, Marchesini G, Nicolino F, Graziani R, Sgarbi D, Loguercio C, Abbiati R, Zoli M. Psychological status and depression in patients with liver cirrhosis. Dig Liver Dis. 2005;37(8):593-600. DOI: 10.1016/j.dld.2005.01.020 9. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kent Kwoh C. Co‐morbid medical and psychiatric illness and substance abuse in HCV‐infected and uninfected veterans. J Viral Hepatitis. 2007;14:890-6. DOI: 10.1111/j.1365-2893.2007.00885.x 10. Capuron L, Schroecksnadel S, Féart C, Aubert A, Higueret D, Barberger-Gateau P, Layé S, Fuchs D. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms.Biol Psychiatry. 2011;70(2):175-82. DOI: 10.1016/j.biopsych.2010.12.006 11. Cargiulo T. Understanding the health impact of alcohol dependence. Am J Health Syst Pharm. 2007;64(5 Suppl 3):S5-11. DOI:10.2146/ajhp060647 12. Carta MG, Hardoy MC, Boi MF et al. Association between panic disorder, major depressive disorder and celiac disease: a possible role of thyroid autoimmunity. J Psychosom Res. 2002;53(3):789-93. DOI: 10.1016/s0022-3999(02)00328-8 13. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue in primary biliary cirrhosis. Gut. 1998;43(5):705-10. DOI: 10.1136/gut.43.5.705 14. Chojnacki C, Walecka-Kapica E, Klupińska G, Wachowska-Kelly P, Żylińska K, Winczyk K, Chojnacki J. Serotonin and melatonin secretion and metabolism in patients with liver cirrhosis. Pol Arch Med Wewn. 2012;122(9):392-7. 15. Chojnacki C1, Wachowska-Kelly P, Błasiak J, Reiter RJ, Chojnacki J. Melatonin secretion and metabolism in patients with hepatic encephalopathy. J Gastroenterol Hepatol. 2013;28(2):342-7. DOI: 10.1111/jgh.12055 16. Corruble E, Barry C, Varescon I, Falissard B, Castaing D, Samuel D. Depressive symptoms predict long-term mortality after liver transplantation. J Psychosom Res. 2011;71(1):32−7. DOI: 10.1016/j.jpsychores.2010.12.008 17. Crum RM, Storr CL, Chan YF. Depression syndromes with risk of alcohol dependence in adulthood: a latent class analysis. Drug Alcohol Depend. 2005;79:71-81. DOI: 10.1016/j.drugalcdep.2005.01.001 18. Culafic DM, Mirkovic DS, Vukcevic MD, Rudic JS. Plasma and platelet serotonin levels in patients with liver cirrhosis. World J Gastroenterol. 2007;13(43):5750-3. DOI: 10.3748/wjg.v13.i43.5750 19. D’Mello C, Swain MG. Liver-brain inflammation axis. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G749-61. DOI: 10.1152/ajpgi. 00184.2011 20. De Bona M, Ponton P, Ermani M. The impact of liver disease and medical complications on quality of life and psychosocial distress before and after liver transplantation. J Hepatol. 2000;33:609-15. 21. Di Martini A, Dew MA, Chaiffetz D, Fitzgerald MG, Devera ME, Fontes P. Early trajectories of depressive symptoms after liver transplantation for alcoholic liver disease predicts long-term survival. Am J Transplant. 2011;11(6):1287-95. DOI: 10.1111/j.1600-6143.2011.03496.x 22. Diaz SL, Doly S, Narboux-Nême N, Fernández S, Mazot P, Banas SM, Boutourlinsky K, Moutkine I, Belmer A, Roumier A, Maroteaux L. 5‐HT(2B) receptors are required for serotonin‐selective antidepressant actions. Molecular Psychiatry. 2012;17:154-63. DOI: 10.1038/mp.2011.159 23. Dobbels F, Vanhaecke J, Dupont L, Nevens F, Verleden G, Pirenne J, De Geest S. Pretransplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening. Transplantation. 2009;87:1497-504. DOI: 10.1097/TP.0b013e3181a440ae 24. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res. 2000;49(5):311-7. DOI: 10.1016/s0022-3999(00)00155-0 25. Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Moles A, Perugorria MJ, Ellis E, Lakey AF, Burt AD, Douglass A et al. Stimulating healthy tissue regeneration by targeting the 5‐HT2B receptor in chronic liver disease. Nat Med. 2011;17:1668–73. DOI: 10.1038/nm.2490 26. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-73. DOI: 10.1002/hep.21327 27. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123(2):476-82.DOI:10.1053/gast.2002.34750 28. Elwing JE, Lustman PJ, Hanlin HL, Clouse R. Depression, anxiety and nonalcoholic steatohepatitis. Psychosom Med. 2006;68:563-9.DOI:10.1097/01. psy.0000221276.17823.df 29. Gilman SE, Abraham HD. A longitudinal study of the order of onset of alcohol dependence and major depression. Drug Alcohol Depend. 2001;63(3):277-86. DOI: 10.1016/s0376-8716(00)00216-7 30. Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Calès P, Garré JB. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry. 2003;4(3):115-8. DOI: 10.1080/15622970310029904 31. Golden J, O’Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry. 2005;27(6):431-8. DOI: 10.1016/j.genhosppsych.2005.06.006 32. Goulding C, O’Connell P, Murray FE. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol 2001; 13(5): 507−11. DOI:10.2147/PPA.S34945 33. Grover VP, Pavese N, Koh SB. Cerebral microglial activation with patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepatitis. 2012;19:e89-96.DOI:10.1111/j.1365-2893.2011.01510.x 34. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD et al. A prospective study of the incidence and open‐label treatment of interferon‐induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry. 2002;7:942-7. DOI: 10.1038/sj.mp.4001119 35. Häuser W, Holtmann G, Grandt D. Determinants of health-related quality of life in patients with chronic liver diseases. Clin Gastroenterol Hepatol. 2004;2(2):157−63. DOI: 10.1016/s1542-3565(03)00315-x 36. Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Seminars in immunopathology. 2009;31(3):283-307. DOI: 10.1007/s00281-009-0164-5 37. Huang X, Liu X, Yu Y. Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms? Front Mol Neurosci. 2017;10:134. DOI: 10.3389/fnmol.2017.00134 38. Huet PM, Deslauriers J, Tran A, Faucher C, Charbonneau J. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol. 2000;95(3):760-7. DOI: 10.1111/j.1572-0241.2000.01857.x 39. Janik MK, Wunsch E, Raszeja-Wyszomirska J, Moskwa M, Kruk B, Krawczyk M, Milkiewicz P. Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: A prospective, single-centre study. Liver Int. 2019;39(1):215-221. doi: 10.1111/liv.13960. 40. Ko FY, Yang AC, Tsai SJ, Zhou Y, Xu LM. Physiologic and laboratory correlates of depression, anxiety, and poor sleep in liver cirrhosis. BMC Gastroenterol. 2013;13:18. DOI: 10.1186/1471-230X-13-18 41. Kraus MR, Schäfer A, Csef H, Faller H, Mörk H, Scheurlen M. Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci. 2001;46(10):2060-5. DOI: 10.1023/a:1011973823032 42. Kuria MW, Ndetei DM, Obot IS, Khasakhala LI, Bagaka BM, Mbugua MN, Kamau J. The Association between Alcohol Dependence and Depression before and after Treatment for Alcohol Dependence. ISRN Psychiatry. 2012;2012:482802. DOI:10.5402/2012/482802 43. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107-15. DOI: 10.1111/j.1469-0691.2010.03432.x 44. Lee K, Otgonsuren M, Younoszai Z, Mir HM, Younossi ZM. Association of chronic liver disease with depression: a population‐based study. Psychosomatics. 2013;54:52–9. DOI: 10.1016/j.psym.2012.09.005 45. Leutscher PD, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, Mørch K, Färkkilä M, Hjerrild S et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 2010;52:430-5. DOI: 10.1002/hep.23699 46. Lotrich FE, Albusaysi S, Ferrell RE. Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment. Neuropsychopharmacology. 2013;38(6):985-95. DOI: 10.1038/npp.2012.263 47. Lu Y, Feng L, Feng L, Nyunt MS, Yap KB, Ng TP. Systemic inflammation, depression and obstructive pulmonary function: a population-based study. Respir Res. 2013;14:53. DOI: 10.1186/1465-9921-14-53 48. Maddock C, Baita A, Orrù MG, Sitzia R, Costa A, Muntoni E, Farci MG, Carpiniello B, Pariante CM. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol. 2004;18(1):41-6. DOI: 10.1177/0269881104040230 49. Martins PD, Sankarankutty AK. Silva Ode C, Gorayeb R. Psychological distress in patients listed for liver transplantation. Acta Cir Bras. 2006;21(Suppl 1): 40−3. DOI: 10.1590/s0102-86502006000700010 50. Mells GF, Pells G, Newton JL, Bathgate AJ, Burroughs AK, Heneghan MA, Neuberger JM, Day DB, Ducker SJ, Sandford RN et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58(1):273-83. DOI: 10.1002/hep.26365 51. Miller LR, Paulson D, Eshelman A, Bugenski M, Brown KA, Moonka D, Abouljoud M. Mental health affects the quality of life and recovery after liver transplantation. Liver Transpl. 2013;19(11):1272-8. DOI: 10.1002/lt.23728 52. Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacol Ther. 2014;40(8):880-92. DOI: 10.1111/apt.12925 53. Musselman DL1, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH. Paroxetine for the prevention of depression induced by high‐dose interferon alfa. N Engl J Med. 2001;344:961-6. 54. Nardelli S, Pentassuglio I, Pasquale C et al. Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients. Metab Brain Dis. 2013;28(2):239-43. 55. Neurauter G, Schröcksnadel K, Scholl-Bürgi S, Sperner-Unterweger B, Schubert C, Ledochowski M, Fuchs D. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab. 2008;9(7):622-7. DOI: 10.2174/138920008785821738 56. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ et al. Clinical, laboratory, and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52:913-24. DOI: 10.1002/hep.23784 57. O’Shea RS, Dasarathy S, McCullough AJ et al. Alcoholic liver disease. Hepatology. 2010;51(1):307-28. DOI: 10.1002/hep.23258 58. Pasco JA, Nicholson GC, Williams LJ, Jacka FN, Henry MJ, Kotowicz MA, Schneider HG, Leonard BE, Berk M. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry. 2010;197(5):372-7. DOI:10.1192/bjp.bp.109.076430 59. Perney P, Lehert P, Mason BJ. Sleep disturbance in alcoholism: proposal of a simple measurement, and results from a 24-week randomized controlled study of alcohol-dependent patients assessing acamprosate efficacy. Alcohol Alcohol. 2012;47(2):133-9. DOI: 10.1093/alcalc/agr160 60. Perng CL, Shen CC, Hu LY, Yeh CM, Chen MH, Tsai CF, Chiang HL, Hung YP, Su VY, Hu YW et al. Risk of depressive disorder following non-alcoholic cirrhosis: a nationwide population-based study. PLoS One. 2014:12;9(2): e88721. DOI: 10.1371/journal.pone.0088721 61. Poole LG, Dolin CE, Arteel GE. Organ-Organ Crosstalk and Alcoholic Liver Disease. Biomolecules. 2017;7(3): pii: E62. doi: 10.3390/biom7030062. 62. Rahman SA, Kayumov L, Shapiro CM. Antidepressant action of melatonin in the treatment of Delayed Sleep Phase Syndrome. Sleep Med. 2010;11(2):131-6. DOI: 10.1016/j.sleep.2009.07.013 63. Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, Miller AH. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry. 2010;15(5):535-47. DOI: 10.1038/mp.2008.58 64. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon‐alpha: recognition and management. CNS Drugs. 2005;19:105-23. DOI: 10.2165/00023210-200519020-00002 65. Raison CL1, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005;66(1):41-8. DOI: 10.4088/jcp.v66n0106 66. Rocca P, Cocuzza E, Rasetti R, Rocca G, Zanalda E, Bogetto F. Predictors of psychiatric disorders in liver transplantation candidates: logistic regression models. Liver Transpl. 2003; 9(7): 721−6. DOI:10.1053/jlts.2003.50133 67. Rogal SS, Dew MA, Fontes P, DiMartini AF. Early treatment of depressive symptoms and long-term survival after liver transplantation. Am J Transplant. 2013;13(4):928-35. DOI: 10.1111/ajt.12164 68. Rogal SS, Landsittel D, Surman O, Chung RT, Rutherford A. Pretransplant depression, antidepressant use, and outcomes of orthotopic liver transplantation. Liver Transpl. 2011;17(3):251-60. DOI: 10.1002/lt.22231 69. Rogal SS, Mankaney G, Udawatta V, Chinman M, Good CB, Zickmund S, Bielefeldt K, Chidi A, Jonassaint N, Jazwinski A et al. Pre-Transplant Depression Is Associated with Length of Hospitalization, Discharge Disposition, and Survival after Liver Transplantation. PLoS One. 2016;11(11): e0165517. 70. Rondanelli M, Faliva MA, Perna S, Antoniello N. Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks. Aging Clin Exp Res. 2013;25(5):499-510. DOI:10.1007/s40520-013-0118-6 71. Ruiz P. Comprehensive textbook of psychiatry. Cambridge Press, 2017. 72. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85. DOI:10.1056/NEJMoa0907929 73. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A, Forton D, Pariante CM. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012;57(6):1379-90. DOI: 10.1016/j.jhep.2012.07.037 74. Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F, Grunze H, Lieb K. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(4):731-46. DOI: 10.1016/s0278-5846(01)00324-4 75. Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R, Friebe A, Heinz A, Kluschke M et al. Hepatitis C treatment in «difficult-to-treat» psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46(4):991-8. DOI:10.1002/hep.21791 76. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443-51. DOI: 10.1053/jhep.2003.50031 77. Schramm C, Wahl I, Weiler-Normann C, Voigt K, Wiegard C, Glaubke C, Brähler E, Löwe B, Lohse AW, Rose M. Health‐related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J Hepatol. 2014;60:618-24. DOI: 10.1016/j.jhep.2013.10.035 78. Sheron N. Alcohol and liver disease in Europe: simple measures have the potential to prevent tens of thousands of premature deaths. J Hepatol. 2016;64:957-967. DOI: 10.1016/j.jhep.2015.11.006 79. Silva I, Rausch V, Seitz HK, Mueller S. Does Hypoxia Cause Carcinogenic Iron Accumulation in Alcoholic Liver Disease (ALD)? Cancers (Basel). 2017;9(11). pii: E145. DOI: 10.3390/cancers9110145 80. Singh N, Gayowski T, Wagener MM, Marino IR. Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis C virus. Clin Transplant. 1997;11(5 Pt 1):406-11. 81. Słomka M, Skrzydło-Radomańska B, Celiński K. Blood serotonin (5-HT) level and 24 hrs urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA) in patients with active liver cirrhosis and in patients with hepatic encephalopathy. Ann Univ Mariae Curie Sklodowska Med. 1991;46:75-80. 82. Stewart CA, Enders FT, Mitchell MM, Felmlee-Devine D, Smith GE. The cognitive profile of depressed patients with cirrhosis. Prim Care Companion CNS Disord. 2011;13pii: PCC.10m01090. doi: 10.4088/PCC.10m01090. 83. Tian Y, Graf R, El-Badry AM, Lesurtel M, Furrer K, Moritz W, Clavien PA. Activation of serotonin receptor‐2B rescues small‐for‐size liver graft failure in mice. Hepatology. 2011;53:253-62. DOI: 10.1002/hep.23960 84. Toffol E, Kalleinen N, Haukka J, Vakkuri O, Partonen T, Polo-Kantola P. Melatonin in perimenopausal and postmenopausal women: associations with mood, sleep, climacteric symptoms, and quality of life. Menopause. 2014;21(5):493-500. doi: 10.1097/GME.0b013e3182a6c8f3. 85. Tomeno W, Kawashima K, Yoneda M, Saito S, Ogawa Y, Honda Y, Kessoku T, Imajo K, Mawatari H, Fujita K et al. Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy. J Gastroenterol Hepatol. 2015;30(6):1009-14. DOI:10.1111/jgh.12897 86. van Os E1, van den Broek WW, Mulder PG, ter Borg PC, Bruijn JA, van Buuren HR. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2007;46(6):1099-103. DOI: 10.1016/j.jhep.2007.01.036 87. Weinstein AA, Kallman Price J, Stepanova M, Poms LW, Fang Y, Moon J, Nader F, Younossi ZM. Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics. 2011;52(2):127-32. DOI: 10.1016/j.psym.2010.12.019 88. Weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann H, Trebst C, Hecker H, Berding G. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronicfatigue and cognitive impairment. Gut. 2006;55(11):1624-30. DOI:10.1136/gut.2005.080267 89. Weissenborn K, Ennen JC, Schomerus H, Rückert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol. 2001;34:768-73. DOI: 10.1016/s0168-8278(01)00026-5 90. Widner B, Ledochowski M, Fuchs D. Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunologicalconsequences. Curr Drug Metab. 2000;1(2):193-204. DOI: 10.2174/1389200003339063 91. World Health Organization. WHO mortality database: raw data files. Geneva: World Health Organization; 2015. 92. Youssef NA, Abdelmalek MF, Binks M, Guy CD, Omenetti A, Smith AD, Diehl AM, Suzuki A. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 2013;33(7):1062-70. DOI:10.1111/liv.12165 93. Zahn A, Seubert L, Jünger J, Schellberg D, Weiss KH, Schemmer P, Stremmel W, Sauer P, Gotthardt DN. Factors influencing long‐term quality of life and depression in German liver transplant recipients: a single‐centre cross‐sectional study. Ann Transplant. 2013;18:327-35. DOI: 10.12659/AOT.883962 94. Zhabenko O, Krentzman AR, Robinson EA, Brower KJ. A longitudinal study of drinking and depression as predictors of insomnia in alcohol-dependent individuals. Subst Use Misuse. 2013;48(7):495-505. DOI: 10.3109/10826084. 2013.781182 95. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:722-9. DOI: 10.1016/j.pnpbp.2010.04.011